A team of Chinese scientists has developed a stem cell therapy that could fundamentally transform how the world treats diabetes. At the heart of the breakthrough is a process that takes a patient's own fat cells, reprograms them into induced pluripotent stem cells (iPSCs), and converts them into islet cells responsible for producing insulin.
When transplanted back into the body, these cells restore pancreatic function naturally, eliminating the need for immunosuppressants and reducing dependence on traditional therapies.
Early trials have delivered remarkable outcomes for both types of diabetes. A 25-year-old woman with Type 1 diabetes was able to stop using insulin within 75 days of the procedure, while a 59-year-old man with Type 2 diabetes became insulin-free in just 11 weeks and has remained off medication for over a year. Global diabetes experts have called the findings extraordinary.
The trial, conducted at Tianjin First Central Hospital, confirmed that the transplanted cells engrafted successfully, created their own vasculature, and enabled patients to produce sufficient insulin independently. Researchers noted significant improvements in glycated haemoglobin levels, reflecting sustained non-diabetic glucose readings over time.
If further developed and applied at scale, the therapy could dramatically reduce the risk of diabetes-related complications such as kidney failure, blindness, and amputation, while potentially cutting long-term healthcare costs worldwide.
The insulin industry alone is worth over USD 20 billion annually in the United States, making the economic implications of a functional cure significant.
Key scientific questions remain, including how long the lab-generated islet cells will remain functional, whether the therapy can be produced at industrial scale, and whether any unknown long-term side effects will emerge.
China is accelerating the next phase of trials, while international researchers are seeking collaboration to expand the scope of the work. With over 500 million people living with diabetes globally, the stakes could not be higher.
